Inhibrx Biosciences posts updated investor presentation to website; exhibit text truncated with no new data disclosed

Inhibrx Biosciences, Inc.

Inhibrx Biosciences (INBX) said it posted an updated corporate presentation to the 'Investors' tab of www.inhibrx.com on September 28, 2026.
The 8-K provides no financial results, guidance, clinical data or deal terms; only the presentation's title slide and forward-looking-statements disclaimer are included in the filing text.
Filing signed by Chief Financial Officer Kelly Deck, dated September 28, 2026; company is a Delaware corporation headquartered at 11025 N. Torrey Pines Road, La Jolla, CA.
Because the exhibit content is not readable here, no specific updates to pipeline, cash runway or trial timelines can be confirmed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.